For U.S. Healthcare Professionals Only
Print | Share | Adjust Font Size Decrease font size Increase font size   Search:
For Patients & Caregivers   |   For Healthcare Professionals
FAQs

LANTUS® Site References

  1. Schreiber SA, Ferlinz K, Haak T. Diabetes Technol Ther. 2008;10(2):121-127.

  2. Schreiber SA, Haak T. Diabetes Obes Metab. 2007;9(1):31-38.

  3. LANTUS® Prescribing Information. September 2009.

  4. McKeage K, Goa KL. Drugs. 2001;61(11):1599-1624.

  5. Raccah D, Bretzel RG, Owens D, Riddle M. Diabetes Metab Res Rev. 2007;23(4):257-264.

  6. Moghissi ES, Korytkowski MT, Dinardo M, et al. Diabetes Care. 2009;32(6):1119-1131.

  7. Center for Disease Control National Diabetes Fact Sheet. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf. Accessed Sept 25, 2009

  8. Nathan DM. N Engl J Med. 2002;347(17):1342-1349.

  9. Alvarsson M, Sundkvist G, Lager I, et al. Diabetes Care. 2003;26(8):2231-2237.

  10. Riddle MC. Am J Med. 2004;116(suppl 3A): 3S-9S.

  11. Holman RR. Diabetes Res Clin Pract. 1998;40(suppl):S21-S25.

  12. UK Prospective Diabetes Study Group. Diabetes. 1995;44:1249-1258.

  13. Hirsch IB, Bergenstal RM, Perkin CG, et al. Clin Diabetes. 2005;23(2):78-86.

  14. Brown JB, Nicholas GA, Perry A. Diabetes Care. 2004;27(7):1535-1540.

  15. American Diabetes Association. Diabetes Care. 2009;32(suppl 1):S13-S61.

  16. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. Endocr Pract. 2007;13(suppl 1):4-68.

  17. Leahy JL. In: Leahy JL, Cefalu WT, eds. Insulin Therapy. New York, NY: Marcel Dekker Inc; 2002: 87-112.

  18. Skyler JS. In: DeFronzo RA, ed. Current Therapy of Diabetes Mellitus. St Louis, Mo: Mosby-Year Book; 1998:108-116.

  19. Lepore M, Pampanelli S, Fanelli C, et al. Diabetes. 2000;49(12):2142-2148.

  20. Blickle, J-F, Hancu N, Piletic M, et al. Diabetes Obes Metab. 2009;11(4):379-386.

  21. Schnipper JL, Barsky EE, Shaykevich S, et al. J Hosp Med. 2006;1(3):145-150.

  22. Knecht LAD, Gauthier SM, Castro JC, et al. J Hosp Med. 2006;1:151-160.

  23. Lubitz CC, Seley JJ, Rivera C, et al. Diabetes Spectrum. 2007;20(1):18-21.

  24. Levetan CS, Passaro M, Jablonski K, Kass M, Ratner RE. Diabetes Care. 1998;21(2):246-249.

  25. Deedwania P, Kosiborod M, Barrett E, et al. Circulation. 2008;117(12):1-10.

  26. Fonseca V. Endocr Pract. 2006;12(suppl 3):108-111.

  27. Nathan DM, Buse JB, Davidson MB, et al. Diabetes Care. 2008;31(12):1-11.

  28. Edelman SV, Morello CM. South Med J. 2005;98:363-371.

  29. Levemir Prescribing Information, May 2007

  30. Porcellati F, Rossetti P, Busciantella NR, et al. Diabetes Care. 2007;30(10):2447-2452.

  31. Plank J, Bodenlenz M, Sinner F, et al. Diabetes Care. 2005;28(5):1107-1112.

  32. Data on file, sanofi-aventis U.S. LLC

  33. Riddle MC, Rosenstock J, Gerich J, on behalf of the Insulin Glargine 4002 Study Investigators. Diabetes Care. 2003;26:3080-3086.

  34. Data on file, sanofi-aventis U.S. LLC.

  35. Yki-Järvinen H, Ziemen M, Dressler A; HOE 901/3002 Study Group. Diabetes Care. 2000;23(8):1130-1136.

  36. Gerstein HC, Yale J-F, Harris SB, et al. Diabetic Med. 2006;23(7):736-742.

  37. Janka HU, Plewe G, Riddle MC, et al. Diabetes Care. 2005;28(2):254-259.

  38. Davies M, Storms F, Shutler S, et al. ATLANTUS® Study Group. Diabetes Care. 2005;28(6):1282-1288.

  39. Hammer H, Klinge A. Int J Clin Pract. 2007;61(12):2009-2018.

  40. American Diabetes Association. American Diabetes Association Complete Guide to Diabetes. 4th ed. Alexandria, VA: American Diabetes Association;2005.

  41. Data on file, sanofi-aventis U.S. LLC.

  42. Korytkowski M, Bell D, Jacobsen C, Suwannasari R, for the FlexPen® Study Team. Clin Ther. 2003;25(11):2836-2848.

  43. Rosenbloom D, Scime J, Elvis B. Can J Hosp Pharm. 1994;47(1):5-7.

  44. Davis E, Christensen C, Nystrom K, et al. J Health Syst Pharm. 2008;65(14):1347-1357.

  45. Riddle MC. Endocrinol Metab Clin N Am. 2005;34:77-98.

  46. Polonsky WH, Fisher L, Guzman S, et al. Diabetes Care. 2005;28(10):2543-2545.

  47. Bethel MA, Feinglos MN. CleveClinJMed. 2005;18(3):199–204.

  48. Funnell M. J Fam Pract. 2007;25(1):36-38.

  49. Mensing C. The Art and Science of Diabetes Self Management Education. Chicago, IL: American Academy of Diabetes Educators; 2006.

  50. Polonsky WH et al. Clin Diabetes. 2004;22(3):147-150.

  51. Campos C. South Med J. 2007;100:812-820.

  52. Wolf MS et al. Patient Educ Couns. 2007;67(3):293-300.

  53. Weiss BD. Health Literacy and Patient Safety: Help Patients Understand. Manual for Clinicians, 2nd ed. Chicago, IL: American Medical Association Foundation and American Medical Association; 2007.

  54. Bode BW, Braithwaite SS, Steed RD, et al. Endocr Pract. 2004;10(suppl 2):71-80.

  55. Clement S, Braithwaite SS, Magee MF, et al. Diabetes Care. 2004;27(2):553-591.

  56. Stratton IM, Adler AI, Neil HAW, et al. BMJ. 2000;321(7258):405-412.

  57. Holman RR, Paul SK, Bethel MA, et al. Engl J Med. 2008;359(15):1577-1589.

  58. AMDA. Diabetes management in the long-term care setting;2008: 1-44, D1, D2.

  59. Umpierrez GE, Smiley D, Zisman A, et al. Diabetes Care. 2007;30(9):2181-2186.

  60. Monnier L, Lapinksi H, Colette C. Diabetes Care. 2003;26(3):881-885.

  61. Apidra® (insulin glulisine [rDNA origin] injection) Prescribing Information. February 2009.

  62. Schober E, Schoenle E, Van Dyk J, et al. J Pediatr Endocrinol Metab. 2002;15(4):369-376.

  63. Data on file, sanofi-aventis U.S. LLC.

  64. American Diabetes Association. Diabetes Care. 2008;31(Suppl 1): S12-S34.

  65. Hoerger JH, Segel JE, Gregg EW, et al. Diabetes Care. 2008;31(1):81-86.

  66. Westphal SA, Palumbo PF. European Endocrine Disease 2007. London, UK: Touch Briefings; 2007;34-36.

  67. Bhargava A. Insulin. 2007;2(2):92-94.

  68. American Diabetes Association. Diabetes Care. 2010;33(suppl 1):S11-S61

  69. Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA; Orals Plus APIDRA® and LANTUS® (OPAL) study group. Diabetes Obes Metab. 2008;10(12):1178-1185.

  70. Bergenstal RM, Johnson M, Powers MA, et al. Diabetes Care. 2008;31(7):1305-1310.

  71. Dailey G, Rosenstock J, Moses RG, Ways K. Diabetes Care. 2004;27(10):2363-2368.

  72. Rosenstock J et al. Diabetologia. 2009;52(9):1778-1788.

  73. Nathan DM, Buse JB, Davidson MB, et al. Diabetes Care. 2009;32(1):193-203.

  74. Meese J. Am J Health-Syst Pharm. 2008;65:1076-1082.

  75. Yki-Järvinen H, Juurinen L, Alvarsson M, et al. Diabetes Care. 2007;30(6):1364-1369.

  76. Queale WS, Seidler AJ, Brancati FL. Arch Intern Med. 1997;157(5):545-552.

Related sites from sanofi aventis >

Important Safety Information for Lantus®

CONTRAINDICATIONS

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

WARNINGS AND PRECAUTIONS

Monitor blood glucose in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Do not dilute or mix Lantus® with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus® via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices and needles must not be shared between patients.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®, and may be life-threatening.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur.

A reduction in the Lantus® dose may be required in patients with renal or hepatic impairment.

DRUG INTERACTIONS

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

ADVERSE REACTIONS

Other adverse reactions commonly associated with Lantus® are injection site reaction, lipodystrophy, pruritus, and rash.

Indications and Usage for Lantus®

Lantus® is a long-acting insulin analog indicated to improve glycemic control in adults and children (6 years and older) with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus® should be administered once a day at the same time every day.

Important Limitations of Use: Lantus® is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Lantus® SoloSTAR® is a disposable prefilled insulin pen.

Please click here for full prescribing information.


Important Safety Information for Apidra®
(insulin glulisine [rDNA origin] injection)

CONTRAINDICATIONS

Apidra® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Apidra® or any of its excipients.

WARNINGS AND PRECAUTIONS

Closely monitor blood glucose in all patients treated with insulin. Change insulin regimens cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. As with all insulin preparations, the time course of Apidra® action may vary by individual or at different times in the same individual and is dependent on many conditions, including the site of injection, local blood supply, or local temperature.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Apidra®, which may be serious.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur. All insulins, including Apidra®, can cause hypokalemia, which if untreated, may be serious.

A reduction in the Apidra® dose may be required in patients with renal or hepatic impairment.

Apidra® for subcutaneous injection should not be mixed with insulins other than NPH. Do not mix Apidra® with any insulin when used in the pump or for intravenous administration. Insulin devices and needles must not be shared between patients.

DRUG INTERACTIONS

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

ADVERSE REACTIONS

Other adverse reactions commonly associated with Apidra® include injection site reactions, lipodystrophy, pruritus, and rash.

Indications and Usage for Apidra®

Apidra® is a rapid-acting insulin analog indicated to improve glycemic control in adults with type 2 diabetes or adults and children (4 years and older) with type 1 diabetes.

When used as a mealtime insulin, the dose of Apidra® should be given within 15 minutes before or within 20 minutes after starting a meal. Apidra® should normally be used in regimens that include a longer-acting insulin.

Please click here for full prescribing information for Apidra®


Click herefor information on Sharps Medical Waste Disposal.

LANTUS® HCP Home | About Insulin Therapy | About LANTUS® | Dosing & Titration | LANTUS® SoloSTAR® Pen | Getting Patients Started | Managing Patient Therapy
Basal-Prandial Therapy | For Your Patients | FAQs | Prescribing Information | About sanofi-aventis | Site Map | Tools & Resources | LANTUS® Patient Site

© 2002-2010 sanofi-aventis U.S. LLC. All rights reserved.
Legal Disclaimer Information and Privacy Policy
Questions or Comments? Click here to contact us.
This site intended for use by US Healthcare Professionals Only.
US.GLA.10.03.006 Last Update: July 2010